Please assess the completion status of the following clinical trial:

Trial Title: Neurocysticercosis: Combined Treatment With Praziquantel (PZQ) and Albendazole (ABZ)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For parent study:~Inclusion Criteria:~* Male or female individuals between 16 to 65 years of age, with a diagnosis of Neurocysticercosis and 20 or less viable cysts.~* Patients with a diagnosis of epilepsy secondary to Neurocysticercosis and a history of one or more spontaneous seizures within the previous year but not longer than 10 years.~* Willingness to complete a minimum of two weeks of hospitalization.~* If female of child bearing potential, negative urine pregnancy testing and willingness to use an adequate method of contraception while on study medications and for at least 3 months following Albendazole therapy.~* Normal laboratory values for hematocrit, platelets, white blood cells and glucose and normal or decreased values for Alanine transaminase, Aspartate transaminase and creatinine.~* Negative PPD measurement and if positive ( \> 9mm induration in the absence of other findings or immunosuppression ) , negative smears for TB.~* Negative fecal exam for Taenia eggs or Strongyloides larvae.~Exclusion Criteria:~* Primary generalized seizures ( e.g., not caused by Neurocysticercosis )~* A history of generalized epileptic status .~* A type of Neurocysticercosis which can expose the patient to increased risk during the study.~* Patients with persistent or progressive symptomatic intracranial hypertension or intracranial hypertension.~* Previous therapy with Albendazole or Praziquantel in the previous year.~* Pulmonary tuberculosis, or symptoms compatible with tuberculosis not otherwise explained.~* Active hepatitis~* Systemic disease that may affect short term prognosis.~* Patients in unstable condition ( consistently abnormal vital signs: body temperature, heart rate, respiratory rate, and blood pressure )~* Pregnancy during antiparasitic treatment~* History of hypersensitivity to Albendazole or Praziquantel~* Concurrent treatment with Cimetidine or Theophylline~* Chronic alcohol or drug abuse~* Unwilling or unable to provide a Computed tomography initially or an Magnetic resonance imaging at 6 months ( as patients with ferromagnetic implants ) , Computed tomography at the end of therapy.~* Unwillingness of subject or legal representative to give written informed consent.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- I. ABZ + ABZ Placebo + PZQ (Type: ACTIVE_COMPARATOR): Albendazole 15 mg / kg / d (until 800 mg / d) + Placebo of Albendazole ( 7.5 mg / Kg / d )+ Praziquantel 50 mg / kg / d (until 3600 mg / d)
- II.- ABZ + ABZ Placebo + PZQ Placebo (Type: ACTIVE_COMPARATOR): Albendazole 15 mg / kg / d ( until 800 mg / d ) + Placebo of Albendazole ( 7.5 mg / Kg / d ) + Placebo of Praziquantel ( 50 mg / kg / d )
- III .- Albendazole + PZQ Placebo (Type: ACTIVE_COMPARATOR): Albendazole 22.5 mg / kg / d (until 1200 mg / d) + Placebo of Praziquantel ( 50 mg / kg / d )~This arm was not used in the first substudy ( initial part and guide to the design of the parent study ) however it will be used henceforward.

Based on this trial design, predict the completion outcome and termination type (if applicable).